$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year
The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Orthopedic device maker Smith & Nephew: BlackRock now top investor
The world’s largest asset management firm, BlackRock Inc., boosts its position in Smith & Nephew to nearly 45 million shares, making it the orthopedic company’s largest institutional shareholder. BlackRock Inc. (NYSE:BLK) increased stake in British orthopedic device maker Smith & Nephew plc (NYSE:SNN) by some 2 million shares, making it the company’s single largest investor. […]